Organization | IFOM

IFOM Report issue

Academic/Hospital Phase 2

Founded: Milan Italy

Organization Overview

First Clinical Trial

2018

NCT03589014

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

IFOM (Istituto FIRC di Oncologia Molecolare) | IFOM, The FIRC Institute of Molecular Oncology

Active Ingredients

Drugs in Phase 2 Trials (15)

capecitabine (xeloda) (1 trial)

ceralasertib (1 trial)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (1 trial)

durvalumab (imfinzi) (1 trial)

fluorouracil (efudex) (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

levoleucovorin (fusilev) (1 trial)

metformin (glucophage) (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (1 trial)

propranolol (inderal) (1 trial)

temozolomide (temodar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Congenital Abnormalities (Phase 2)

Hemangioma, Cavernous, Central Nervous System (Phase 2)

Microsatellite Instability (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial APIs: 15